Compass Therapeutics annual current ratio
2019
2020
2020
2021
2022
2023
2024
2025
Compass Therapeutics Current Ratio Growth & History (CMPX)
Compass Therapeutics's current ratio was 15.02 for fiscal 2025.
View full Compass Therapeutics company overviewCompass Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 15.02 | 0.06 | +0.41% |
| 2024 | 2024-12-31 | 14.96 | −4.77 | −24.16% |
| 2023 | 2023-12-31 | 19.73 | 7.68 | +63.74% |
| 2022 | 2022-12-31 | 12.05 | −1.79 | −12.94% |
| 2021 | 2021-12-31 | 13.84 | 8.87 | +178.36% |
| 2020 · Dec 31 | 2020-12-31 | 4.97 | — | — |
| 2020 · Mar 31 | 2020-03-31 | 0.03 | −0.03 | −48.07% |
| 2019 · Mar 31 | 2019-03-31 | 0.06 | — | — |
Compass Therapeutics quarterly current ratio
As of Mar 31, 2018
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q4.19
Q4.20
Q1.21
Q2.21
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 11.22 | 3.55 | +46.36% |
| Q1 2026 | 2026-03-31 | 19.04 | 10.71 | +128.49% |
| Q4 2025 | 2025-12-31 | 15.02 | 0.06 | +0.41% |
| Q3 2025 | 2025-09-30 | 17.82 | −14.02 | −44.05% |
| Q2 2025 | 2025-06-30 | 7.66 | −8.49 | −52.55% |
| Q1 2025 | 2025-03-31 | 8.33 | −32.41 | −79.55% |
| Q4 2024 | 2024-12-31 | 14.96 | −4.77 | −24.16% |
| Q3 2024 | 2024-09-30 | 31.84 | 13.58 | +74.38% |
| Q2 2024 | 2024-06-30 | 16.15 | −1.92 | −10.64% |
| Q1 2024 | 2024-03-31 | 40.74 | 24.33 | +148.31% |
| Q4 2023 | 2023-12-31 | 19.73 | 7.68 | +63.74% |
| Q3 2023 | 2023-09-30 | 18.26 | 5.46 | +42.69% |
| Q2 2023 | 2023-06-30 | 18.07 | 5.71 | +46.20% |
| Q1 2023 | 2023-03-31 | 16.41 | 1.38 | +9.17% |
| Q4 2022 | 2022-12-31 | 12.05 | −1.79 | −12.94% |
| Q3 2022 | 2022-09-30 | 12.80 | 9.08 | +244.07% |
| Q2 2022 | 2022-06-30 | 12.36 | 8.25 | +200.43% |
| Q1 2022 | 2022-03-31 | 15.03 | 11.19 | +291.55% |
| Q4 2021 | 2021-12-31 | 13.84 | 8.87 | +178.36% |
| Q3 2021 | 2021-09-30 | 3.72 | −2.26 | −37.80% |
| Q2 2021 · Jun 30 | 2021-06-30 | 4.11 | −1.68 | −29.01% |
| Q1 2021 · Mar 31 | 2021-03-31 | 3.84 | 3.80 | +11360.67% |
| Q4 2020 · Dec 31 | 2020-12-31 | 4.97 | 4.97 | +4267388.25% |
| Q2 2021 · Sep 30 | 2020-09-30 | 5.98 | 5.97 | +61812.80% |
| Q1 2021 · Jun 30 | 2020-06-30 | 5.80 | 5.74 | +10253.22% |
| Q4 2020 · Mar 31 | 2020-03-31 | 0.03 | −0.03 | −48.07% |
| Q4 2019 · Dec 31 | 2019-12-31 | 0.00 | −0.07 | −99.83% |
| Q2 2020 | 2019-09-30 | 0.01 | −0.04 | −78.67% |
| Q1 2020 | 2019-06-30 | 0.06 | −0.09 | −61.09% |
| Q4 2019 · Mar 31 | 2019-03-31 | 0.06 | 0.06 | +8819.31% |
| Q3 2019 | 2018-12-31 | 0.07 | — | — |
| Q2 2019 | 2018-09-30 | 0.05 | — | — |
| Q1 2019 | 2018-06-30 | 0.14 | — | — |
| As of Mar 31, 2018 | 2018-03-31 | 0.00 | — | — |
Compass Therapeutics current ratio trends
Over the last five fiscal years, Compass Therapeutics's current ratio increased from 4.97 to 15.02, a change of 10.05. The latest reported quarter, Q2 2026, shows 11.22.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Compass Therapeutics source filings ↗